Seek Returns

KYMR vs. RGEN: Kymera Therapeutics vs. Repligen Stock Comparison

How do Kymera Therapeutics (KYMR) and Repligen (RGEN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Kymera Therapeutics (KYMR) and Repligen (RGEN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but KYMR is classified in Biotechnology while RGEN is classified in Life Sciences Tools & Services.

Repligen (RGEN) has more than two decades of public-market history since April 29, 1986, whereas Kymera Therapeutics (KYMR) listed on August 21, 2020 and has a much shorter record to draw on.

Company profile comparison for Kymera Therapeutics (KYMR) and Repligen (RGEN)
Profile ItemKYMRRGEN
NameKymera Therapeutics Inc.Repligen Corporation
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyLife Sciences Tools & Services
GICS Sub-IndustryBiotechnologyLife Sciences Tools & Services
Market Capitalization11.25 billion USD11.09 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateAugust 21, 2020April 29, 1986
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

KYMR
RGEN
GSPC
Loading price history…
Kymera Therapeutics (KYMR) vs. Repligen (RGEN), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Kymera Therapeutics (KYMR) and Repligen (RGEN). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Kymera Therapeutics (KYMR) and Repligen (RGEN). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Kymera Therapeutics (KYMR) and Repligen (RGEN)
MetricKYMRRGEN
Total Return (1Y)131.52%23.28%
Total Return (3Y, Annualized)111.65%6.20%
Total Return (5Y, Annualized)15.68%-8.41%

Risk Profile

Drawdown History

KYMR
RGEN
GSPC
Loading price history…
Kymera Therapeutics (KYMR) vs. Repligen (RGEN), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Kymera Therapeutics (KYMR) and Repligen (RGEN). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Kymera Therapeutics (KYMR) and Repligen (RGEN)
MetricKYMRRGEN
Volatility (1Y, Annualized)62.83%46.73%
Beta (5Y)2.001.11
Max Drawdown (5Y)-83.27%-64.67%
Avg. Volume (3M)833.05K1.18M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
KYMR and RGEN are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Kymera Therapeutics (KYMR) and Repligen (RGEN)
MetricKYMRRGEN
Sharpe Ratio (1Y)2.030.41
Sortino Ratio (1Y)4.160.60

Profitability

ROE (TTM)

Both Kymera Therapeutics (KYMR) at -27.29% and Repligen (RGEN) at -0.57% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

-27.29%

Max
109.18%
Q3
6.23%
Median
-26.66%
KYMR
-27.29%
Q1
-64.05%
Min
-167.77%

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

-0.57%

Max
109.18%
Q3
6.23%
RGEN
-0.57%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Kymera Therapeutics (KYMR) vs. Repligen (RGEN): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Repligen (RGEN) reports a negative net margin of -1.47%, usually indicating a net loss over the period. Meanwhile Kymera Therapeutics (KYMR) reports 0.00%, ranking against industry peers normally.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
18.05%
Q3
4.78%
KYMR
0.00%
Median
0.00%
Q1
-4.14%
Min
-17.05%

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

-1.47%

Max
18.05%
Q3
4.78%
Median
0.00%
RGEN
-1.47%
Q1
-4.14%
Min
-17.05%
Loading chart…
Kymera Therapeutics (KYMR) vs. Repligen (RGEN): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Kymera Therapeutics (KYMR) reports a negative operating margin of -396.04%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Repligen (RGEN) reports 6.19%, ranking against industry peers normally.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

-396.04%

Max
83.12%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
KYMR
-396.04%

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.19%

Max
83.12%
Q3
14.77%
RGEN
6.19%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Kymera Therapeutics (KYMR) vs. Repligen (RGEN): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Kymera Therapeutics (KYMR) and Repligen (RGEN)
MetricKYMRRGEN
ROE (TTM)-27.29%-0.57%
ROA (TTM)-17.64%1.40%
Net Margin (TTM)0.00%-1.47%
Operating Margin (TTM)-396.04%6.19%
Gross Margin (TTM)0.00%53.77%

Growth

Revenue Growth

Repligen (RGEN) at 16.36% is around its peer norm for revenue growth, while Kymera Therapeutics (KYMR) at -16.70% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Loading chart…
Kymera Therapeutics (KYMR) vs. Repligen (RGEN): A comparison of their Revenue Growth across different time periods.

EPS Growth

Neither Kymera Therapeutics (KYMR) nor Repligen (RGEN) reports a EPS growth value for this period, so a direct comparison isn't possible.

Loading chart…
Kymera Therapeutics (KYMR) vs. Repligen (RGEN): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Kymera Therapeutics (KYMR) and Repligen (RGEN)
MetricKYMRRGEN
Revenue Growth (YoY)-16.70%16.36%
Revenue Growth (3Y CAGR)-5.74%-2.70%
EPS Growth (YoY)----
EPS Growth (3Y CAGR)---35.73%

Financial Strength

Current Ratio (MRQ)

Both Kymera Therapeutics (KYMR) at 11.13 and Repligen (RGEN) at 9.88 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

11.13

Max
25.13
Q3
12.13
KYMR
11.13
Median
5.52
Q1
2.47
Min
0.10

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.88

Max
25.13
Q3
12.13
RGEN
9.88
Median
5.52
Q1
2.47
Min
0.10
Loading chart…
Kymera Therapeutics (KYMR) vs. Repligen (RGEN): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Kymera Therapeutics (KYMR) at 0.05 and Repligen (RGEN) at 0.33 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.05

Max
1.42
Q3
0.65
Median
0.15
KYMR
0.05
Q1
0.02
Min
0.00

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.33

Max
1.42
Q3
0.65
RGEN
0.33
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Kymera Therapeutics (KYMR) vs. Repligen (RGEN): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Kymera Therapeutics (KYMR) and Repligen (RGEN)
MetricKYMRRGEN
Current Ratio (MRQ)11.139.88
Debt / Equity (MRQ)0.050.33
Net Debt / EBITDA---1.19

Dividends

Dividend Yield (TTM)

Neither Kymera Therapeutics (KYMR) nor Repligen (RGEN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

KYMR
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

RGEN
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Kymera Therapeutics (KYMR) vs. Repligen (RGEN): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Kymera Therapeutics (KYMR) nor Repligen (RGEN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

KYMR
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

RGEN
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Kymera Therapeutics (KYMR) vs. Repligen (RGEN): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Kymera Therapeutics (KYMR) and Repligen (RGEN)
MetricKYMRRGEN
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

Neither Kymera Therapeutics (KYMR) nor Repligen (RGEN) reports a P/E ratio value for this period, so a direct comparison isn’t possible.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
KYMR
--

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
RGEN
--
Loading chart…
Kymera Therapeutics (KYMR) vs. Repligen (RGEN): Neither stock reports P/E ratio, so the chart shows available benchmark boxes without value markers.

P/S Ratio (TTM)

Repligen (RGEN) at 13.77 prices around its industry’s typical P/S ratio, while Kymera Therapeutics (KYMR) at 110.00 clears its benchmark range — KYMR looks notably rich on sales.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

110.00

KYMR
110.00
Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
Min
0.01

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.77

Max
58.18
Q3
25.77
RGEN
13.77
Median
7.30
Q1
3.01
Min
0.01
Loading chart…
Kymera Therapeutics (KYMR) vs. Repligen (RGEN): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Repligen (RGEN) at 4.70 is valued about in line with its industry on P/B ratio, while Kymera Therapeutics (KYMR) at 6.96 carries an above-peer premium to book — KYMR is pricier on assets.

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.96

Max
13.53
KYMR
6.96
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.70

Max
13.53
Q3
6.54
RGEN
4.70
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Kymera Therapeutics (KYMR) vs. Repligen (RGEN): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Kymera Therapeutics (KYMR) and Repligen (RGEN)
MetricKYMRRGEN
P/E Ratio (TTM)----
P/S Ratio (TTM)110.0013.77
P/B Ratio (MRQ)6.964.70
Free Cash Flow Yield (TTM)-1.46%1.01%